Goldman Sachs Added Elan Corp. plc (ELN) to its Conviction Buy List
More News related to ELN
- Notable Analyst Rating Changes 8/29: CBT, NZ, INCY Upgraded; WBD, ENER, WSM Downgraded
- Pre-Open Movers 8/29: Dell Falls On Earnings/Margin Miss, Magma Design (LAVA) Down on Results/Guidance
- Morgan Stanley Starts Elan (ELN) at Overweight
- FDA Issues Complete Response Letter for Paliperidone Palmitate for the Treatment of Schizophrenia
- Deutsche Bank Notes Tysabri PML Patients are Recovering (BIIB, ELN)
More News related to Analyst Comments
- ARGUS Maintains Hold Rating on Wyeth (WYE)
- Dell (DELL): Colour on quarter
- Deutsche Bank Cuts Price Target on Sigma Designs (SIGM) to $25; Maintains Buy
- Citi Reiterates 'Buy' Rating on Marvell Technology (MRVL)
- Affymax (AFFY) "Significantly Undervalued"; Buy on Weakness -Baird
Goldman Sachs added Elan Corp. plc (NYSE: ELN) to its Conviction Buy List.
Elan Corporation, plc operates as a neuroscience-based biotechnology company primarily in Ireland and the United States.
Related Categories
Analyst CommentsStocks Mentioned
-0.21Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
